Litchfield Hills Research Predicts SLXN FY2027 Earnings

Silexion Therapeutics Corp (NASDAQ:SLXN) – Analysts at Litchfield Hills Research issued their FY2027 EPS estimates for shares of Silexion Therapeutics in a report issued on Monday, September 21st. Litchfield Hills Research analyst T. O’neill anticipates that the company will post earnings of ($1.84) per share for the year. The consensus estimate for Silexion Therapeutics’ current full-year earnings is ($4.70) per share.

Silexion Therapeutics (NASDAQ:SLXN) last issued its quarterly earnings results on Saturday, August 15th. The company reported ($5.17) EPS for the quarter, topping the consensus estimate of ($21.20) by $16.03.

Several other research analysts have also recently commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Silexion Therapeutics in a research report on Friday, September 11th. Maxim Group cut Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 29th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Silexion Therapeutics presently has an average rating of “Hold”.

Silexion Therapeutics Stock Performance

NASDAQ:SLXN opened at $0.32 on Tuesday. Silexion Therapeutics has a 52-week low of $0.30 and a 52-week high of $42.60. The company has a market cap of $1.75 million, a P/E ratio of -0.01 and a beta of -0.36. The stock’s 50-day simple moving average is $1.03 and its 200 day simple moving average is $5.25.

Silexion Therapeutics Company Profile

Silexion Therapeutics Ltd. is an Israel-based clinical-stage biotechnology company focused on developing RNA-based treatments for solid tumors driven by mutations in the KRAS gene. The company’s research is centered on gene-silencing technologies designed to inhibit KRAS, an important cancer-promoting protein that has historically been difficult to target with conventional therapies.

Silexion’s development programs include SIL-204, an investigational small interfering RNA (siRNA) therapy designed to target KRAS mutations, including KRAS G12D, a frequently observed mutation in pancreatic cancer.